Referee #2
Several neurological conditions are associated with mutations in beta III tubulin. Tischfield et al (2010) have reported that a subset of these mutations associated with particularly severe neurological defects are found in the H12 alpha helix of beta tubulin, a region shown by previous in vitro experiments to be involved in kinesin motility. Tischfield et al demonstrated that these mutations when expressed in yeast cells did indeed interfere with kinesin localisation and motility.
In this paper Niwa and Hirokawa report that the beta tubulin mutants identified by Tischfield et al when ectopically expressed in neuronal cells in primary culture affect axonal transport, localisation of proteins and the binding of kinesin to microtubules in extracts. This is the first direct demonstration of these effects in neuronal cells and supports disruption of axonal transport as a possible mechanism to explain the neuronal defects caused by these mutants.
The experiments are well executed and support the conclusion that tubulin mutations causing particular neurological defects disrupt axonal transport. However there are several issues with the paper as written.
1) There is a failure to acknowledge and discuss the previous in vivo work. The introduction and discussion should clarify what has been done before and what is novel about the current work. Tischfield et al (2010) have already identified the mutations in the H12 helix and demonstrated in yeast cells that they affected kinesin binding to microtubules.
For example: P3 L21 Tischfield et al (2010) propose several potential mechanisms P15 L15 authors repeat their claim that molecular mechanisms are not well clarified. However they are better clarified than the authors suggest. P14 L9 Authors state "physiological relevance of these (in vitro) findings is unknown" However Tischfield et al have demonstrated that these mutations do affect Kinesin function in vivo and are therefore of physiological relevance.
2) The authors report that co-expression of the mutant tubulins is sufficient to cause a large disruption of both axonal transport and binding of kinesins to microtubules in extracts. In the discussion they assume that the effect they observe is the same as found in axonal cells in vivo. However as the authors point out the tub3 mutant isoform may only form some 10% of the total tubulin in vivo when expressed as one of the endogenous genes. In this paper the authors ectopically express the tubulin mutants in cultured cells but do not directly measure the level of the mutant tubulin protein expressed. They should therefore make clear in the discussion that their results only apply to the unknown level of mutant tubulin expressed in the cells in their tests. That blockage of axonal transport and kinesin binding could be caused by a 10% expression level and is the actual cause of the defects observed in neurological disease is still speculative and remains to be definitively shown.
The model illustrated in Fig 8d (p13L6) speculates on a potential mechanism to explain the action of low mutant tubulin concentrations incorporated in microtubules. This should be moved to the discussion.
P15 Authors assume that the 10% level is sufficient to explain effect. This needs revising. Also unclear that in vivo the mutant tubulins are still only forming 10% of total tubulin.
3) Many of the images (fig1 and elsewhere) appear saturated making it difficult to visually verify the claims on localisation and expression levels. Images should be adjusted to avoid saturation. 4) P5 L16 "strongly affected" The difference seems small. These statements need to be backed by quantitation. Images of the other mutants should be shown in supplementary data.
5) P4 L1, p13
The authors state their aim as providing insight into basic molecular mechanisms of neuronal morphogenesis. Whilst this present approach certainly has promise of this in the future there is nothing in the current work to illustrate this. This speculation should be limited to the discussion. 6) P4 L18 and figS1 legend states that L228P is cytoplasmic. However fig S1 shows some structures in the cytoplasm, which are not visible in the other "cytoplasmic" mutants. If these are not microtubules the authors should explain what they are. 7) P6 L15 fig1c (also fig2 etc). The most significant effect in the mutants seems to be pausing of the vesicles. The authors should comment on this. Also the comment (L19) that only a few vesicles were observed might suggest that loss of vesicle attachment is the main cause of loss of transport rather than slower movement or any of the other parameters mentioned. 8) P8 L20, p9L9. Authors state here and elsewhere in the paper that "significant amount of Kif5 were released from microtubules". The authors present no data that the Kif5 and other kinesins were ever attached to the microtubules to then be released. This should be rephrased and speculation on the potential mechanisms (as in fig8d) moved to the discussion. 9) P10 L10 onwards. The authors argue that since Kif21 mutants associated with disease cause similar effects to the tubulin mutants in their assay the tubulin mutants must reflect a "diseaseassociated state" and therefore that E410 and D417 can change the properties of Kifs in neurons. This seems a rather large inference to make.
Other minor points: P4 L13 Needs references for the mutants. P6 L5 states 10 obervations, figure legend states n=6 P11 L5. The structural data does not "predict" the effect of the tubulin mutants on accumulation of Kif2 P11 L19 Tub3 was the only gene analysed up to this point. P13 L22 authors state E410K and D417H are specific. Next sentences says other mutants are "more specific" unclear what they mean.
Fig1b graph. The graph needs to clearly show how many time points are included. Would a bar chart not be more appropriate as the time differences are not constant the lines joining the data points are misleading. P3 L13  P4 20  P5 L4  P7 L13,14  P9 L9  P11 L12  P12 L2, L9, L12, L14, L15, L16, L18  P13 L6, 7, 9  P14 L22  P15L7, L14,L17 P17 L18, p18 L10 missing units Referee #3
Niwa and Hirokawa report a series of experiments providing molecular explanation for inhibition of axonal transport of vesicles and mitochondria in neuronal diseases caused by certain mutations in β-tubulin. The authors demonstrate that two mutations occurring in H12 helix of β-tubulin, affect the binding of kinesin motors by changing the charge of this alpha-helix and thereby reducing the affinity of kinesins for β-tubulin. The manuscript is clearly written and the work could be interesting to the broad spectrum of EMBO readers. However, there are several major (especially the effect on dynein, mitochondria / VAMP2 quantifications and the effect on neuronal morphology) and some minor issues that should be addressed first.
Major comments:
1. It is stated that "Microtubules were not significantly affected by expression of these tubulin mutants as described before (data not shown)." The authors should show that these mutations in tubulin do not affect to posttranslational modifications like tyrosination or acetylation and perform live imaging experiments of microtubule dynamics.
2. The authors use GFP-VAMP2 as a marker for vesicular axonal transport. It is written "Indeed, GFP-VAMP2 specifically accumulated in axons when co-transfected with WT-TUBB3 to hippocampal neurons at 10 div (Fig. 1A , left panel and supplementary Movie S1)". Subcellular localization of GFP-VAMP2 is consistent among the main figures. But if one compares GFP-VAMP2 on Figure 1A with GFP-VAMP2 on Figure S1B , it looks very much diffuse in the nucleus, soma, dendrites and axon on the later one. Why do this individual experiment look so different? 3. The authors state "In TUBB3(D417H)-expressing cells, the amount of GFP-VAMP2 mis-sorted to dendrites (Fig. 1A, +D417H , arrow heads) was increased and the polarized localization of GFP-VAMP2 was diminished". If they would like to keep the statement in the text, the authors should show the evidence (images + quantification). Figure 1A should be supported by quantification of GFP-VAMP2 polarity after overexpression of wt, D417H and R62Q mutants, for example, by measuring the ratio of fluorescence in dendrites compare to axon.
4. The number of mitochondria is moving in 5 min. What does that mean? This is not explained well in methods. How long was the axon region that was analyzed... ? How many mitochondria and cells taken into this analysis. Figure 2A : the kymographs show bi-directional movement of mitochondria in axon, what is quantified in the graph? Both directions or only anterograde movements? Is the retrograde transport affected as well? From this and the other figures it looks like that axonal trafficking is inhibited in general. Morover, the number of mitochondria in axons of TUBB3(D417H)-expressing cells was reduced compared to that in control neurons (Fig. 2B ), but they don´t show either any axonal marker or quantification. The authors should quantify the data much better (like velocity, pause rate, % of retrograde and anterograde movement like the analyses performed by Brickley K, Stephenson FA. J Biol Chem. 2011) and show a 'mobility' marker that is not effected by the tubulin mutation.
5. Minor criticisms:
1. The authors found that two TUBB3 mutants, TUBB3 (E410K) and TUBB3 (D417H), strongly affected the axon specific localization of GFP-VAMP2 (Fig. 1A, central panel and graph) . But in the figure 1A they only show one of these mutation. Both mutants should be shown 2. Why most of E410K images have different signal-to-noise ratio compare to controls? Please make the necessary changes.
3. In the FRAP experiments ( Fig 1B) the authors do not explain how they have performed and analysed these experiments. They should show the complete graph, with the values before bleaching, the recovery and how these values reach the plateau? They comment that TUBB3(E410K) and TUBB3(D417H))-expressing cells did not recover at 5 min. But, what happen if you wait longer? Do they reach a plateau after 30 minutes? Is the plateau changing or only the slope of the recovery?
4. Figure 4 -it would be better to convert all images on this figure to grey scale. Additionally is it not clear how "tips" and "shafts" of axons are defined. Is the total length of axon (excluding the growth cone) measured as mean grey value and considered as "shaft" or only a fragment? Figure 5A does not exist, should this be S2A?
Supplementary
6. "As control experiments showing that the accumulation in hippocampal neurons reflect the activity of KIFs and can detect disease-associated deficiency of motor proteins, we expressed a rigor mutant of KIF21A (Nakata & Hirokawa, 1995) , and a KIF21A mutant causing a neuronal disease, congenital fibrosis of extraocular muscle type 1 (CFEOM1) (Lu et al, 2008; Yamada et al, 2003) . Introducing of these two mutants into GFP-hKIF21A420 changed the tipaccumulation (Fig 5B) , suggesting that this assay can detect motor deficiencies and can reflect the disease-associated state." This sentence is somehow not very clear. GFP-hKIF21A420 has not been introduced in the text before and this can be deleted from text because its not essential.
7. How do the authors know that they have at least 10% mutant tubulin incorporated. The data should be shown. Response to reviewers Reviewer#1 suggested us to show the relevance of our findings to human symptoms to support the conclusion of this paper. We totally agree with Reviewer#1 that in vivo experiment is required to publish a paper in EMBO Journal. Thus, we performed in utero electroporation and found that E410K and D417H mutations, expression of which inhibit KIFs and axonal transport in cultured neurons, affect axon development in vivo. This phenotype is quite similar to symptoms of severe CFEOM3 caused by these two mutations. Furthermore, we presented evidence that inhibition of an axonal transport KIF, KIF1Bb, induces the same phenotype. Considering the results in cultured neurons, these data consistently support our conclusion that these two tubulin mutations inhibit neuronal KIFs, axonal transport and causes severe neuropathies. Reviewer#2 and #3 supported the significance and advance of this study, but these reviewers required some important experiments and rewriting of the manuscript in order to more precisely present the results and more clarify the advance of this study.
According to the reviewers' suggestions, we improved our manuscript as described below:
Referee #1 Along the lines suggested by Reviewer#1, we improved our manuscript by performing many in vivo experiments and adding new data. Furthermore, other two reviewers have constructively admitted the advance and supported the importance of this work that is more clearly written in the revised manuscript. Thus, we now think this revised manuscript is suitable for publication in the EMBO J.
To show that in vivo phenotypes are relevant to the results of cultured neurons, in utero electroporation experiments were performed. When TUBB3(E410K) and TUBB3(D417H) mutants were expressed in embryonic brains, axon elongation was significantly inhibited in cortical neurons (new Figure 9) . Based on the cultured neuron experiments, we have suggested that these tubulin mutants are incorporated to microtubules and inhibit the axonal localization of kinesins and induce loss of axonal transport. To test this hypothesis in vivo, we electroporated TUBB3(S172P, D417H) that is not incorporated to microtubules and that does not inhibit KIFs and axonal transport ( Figure  8 ). Consistent with our hypothesis, TUBB3(S172P, D417H) did not change axon elongation in vivo ( Figure 9 ).
In addition, this work lacks analysis of the consequences of TUBB3 mutant over-expression in relation to the distribution of endogenous VAMP2 and Rab3a.
In the normal conditions, these proteins are localized to axons. However, because TUBB3 mutants inhibit the axon development (Figure 9) , we cannot observe "mislocalization" of endogenous axonal proteins in vivo.
To observe axonal transport, we have co-transfected these markers to cultured neurons at 10 div and observed at 24 hours later (Figure 1) . In this condition, we cannot detect the "mislocalization" because endogenous axonal proteins have already been transported to axons when we transfect these vectors. We used axonal proteins such as VAMP2 and Rab3A as markers for axonal transport as these are broadly used in the previous studies (Niwa et al, 2008; Song et al, 2009 ). The important message from these experiments is that "axonal transport" is inhibited by these TUBB3 mutants in a dominant-negative manner. Now, we don't think mislocalization of specific cargos is the causes of axonal defects in TUBB3-mutants expressed cells. Our data suggest that TUBB3(E410K) and TUBB3(D417H) mutations inhibit the function of axonal transport KIFs and cause loss of axonal transport. Because axonal transport provides precursors of axons, we suggest that it is the cause of axonal phenotype observed in in vivo experiments and severe CFEOM3 patients. While previous knockout studies also support this conclusion as Reviewer#2 and #3 suggest, we newly performed in vivo experiments. Our knockdown experiments demonstrated that the reduction of one of the KIFs, KIF1Bb, also causes similar axonal defect phenotype in brains (Figure 9 ). Thus, all the results and previous studies collectively support our conclusion. Thanks to the revewer#1's good suggestion, we could improve our paper. Poirier et al., Hum Mol Genet 19, 4462, 2010) .
Finally, following the authors interest, they should have investigated whether or not kinesin/transport defects also occur in cells derived from patients affected by these mutations (as in
We also think using cells derived from patients is very interesting, but culturing human neurons is impossible in ordinary methods. Truly, Poirier et al. did not use cultured neurons derived from patients (Poirier et al, 2010) . Previous studies have mainly used yeast cells or cultured fibroblasts derived from patients (Jaglin et al, 2009; Poirier et al, 2010; Tischfield et al, 2010) . Furthermore, previous studies have analyzed mitotic KIFs in yeast, but not neuronal KIFs (Tischfield et al, 2010) . However, TUBB2 and TUBB3 mutations cause neuronal diseases. In yeast cells and fibroblasts, one cannot observe neuron specific phenomena such as axonal accumulation of KIFs, axonal transport and axon development. In order to more directly analyze the molecular pathology of neuronal diseases caused by tubulin mutations, we think our methods is superior to those rely on cultured fibroblasts or yeast cells. Our approach clearly suggests that the function of kinesin superfamily proteins and axonal transport are significantly changed by two b-tubulin mutations, which previous approaches could not show (Jaglin et al, 2009; Poirier et al, 2010) . To clarify the progress in this study, we added the following sentences in the introduction and discussion: " Because microtubules modulate the functions of a variety of proteins, such as molecular motors and microtubule-associated proteins (MAP), it is speculated that b-tubulin mutations induce a variety of symptoms. However, previous analyses have relied on yeast cells expressing tubulin mutants or fibroblasts derived from patients. As these studies have not well investigated neuronal cells nor analyzed axonal transport performed by KIFs, the molecular mechanisms of these neuronal defects remains largely elusive. " (in the Introduction)
"In this paper, we found that the H12 helix was essential for the axonal tip-accumulation of KIFs in neurons (Figures 4-6 ), ectopic expression of H12 mutants leads to defective axonal transport and inhibited axon development in vivo (Figure 9 A-C). While previous studies have analyzed the effect of these mutations on mitotic kinesins in yeast cells, our results would more clearly and directly suggest the phenomena causing in CFEOM3 patients. " ( in the Discussion) Nevertheless, as Reviewer#1 suggests, it will be interesting and significant that the results obtained in this study are confirmed in patients' neurons. It will clarify some important issues that our methods cannot address. For this purpose, neurons derived from human iPS cells would help but it is beyond the scope of this single paper. Thus, these points are discussed in the revised manuscript as below: " Because our assay used CMV and CAG promoters and unknown copy numbers of transfected vectors, we could not quantify the amount of tubulin incorporated into microtubules in our system.
However, we think our results give some indication to this question. Microtubules are composed of a-and b-tubulin dimers. The size of each tubulin dimer is 8 nm (Nogales et al, 1999) . Our analysis showed that TUBB3(E410K) and TUBB3(D417H) were incorporated to microtubules in cells and could inhibit axonal transport (Figures S1 and 8A) . The inhibition of motor domain accumulation, axonal transport and axon development were not observed when the incorporation of mutant tubulin was perturbed by introducing the additional S172P mutation (Figures 8 and 9) . Thus, these tubulin mutants need to be co-assembled with normal microtubules to induce neuronal phenotypes. If the 10% mutant TUBB3 is properly incorporated and evenly distributed in neuronal microtubules in CFEOM3 patients, the distance between TUBB3 mutants is about 80 nm, meaning that KIFdependent axonal transport is affected every 80 nm ( Figure 9D ). This distance is short enough to cause an effect because the length of axonal transport is in the order of millimeters to meters (Hirokawa et al, 2010) . To more quantitatively analyze this, it needs to quantify how much amount We thank Reviewer#1 very much for his/her critical but helpful discussion. Thanks to his or her suggestions, we can include new in vivo data in the revised manuscript (Figure 9 ) and significantly improve our manuscript. Moreover, we could clarify what previous works have shown and what is new in this paper.
Referee #2
Several neurological conditions are associated with mutations in beta III tubulin. Tischfield et al (2010) In this paper we show that KIFs that transport neuronal cargos are affected in a dominant-negative manner.
For example: P3 L21 Tischfield et al (2010) propose several potential mechanisms We changed it as follows: " Because microtubules modulate the functions of a variety of proteins, such as molecular motors and microtubule-associated proteins (MAP), it is speculated that b-tubulin mutations induce a variety of symptoms. However, previous analyses have relied on yeast cells expressing tubulin mutants or fibroblasts derived from patients. As these studies have not well investigated neuronal cells nor analyzed axonal transport performed by KIFs, the molecular mechanisms of these neuronal defects remains largely elusive. " (in the Introduction)
P15 L15 authors repeat their claim that molecular mechanisms are not well clarified. However they are better clarified than the authors suggest.
We deleted the sentence.
P14 L9 Authors state "physiological relevance of these (in vitro) findings is unknown" However Tischfield et al have demonstrated that these mutations do affect Kinesin function in vivo and are therefore of physiological relevance.
Yes they are. We changed them as following: " In this paper, we found that the H12 helix was essential for the axonal tip-accumulation of KIFs in neurons (Figures 4-6 ), ectopic expression of H12 mutants leads to defective axonal transport and inhibited axon development in vivo (Figure 9 A-C) . While previous studies have analyzed the effect of these mutations on mitotic kinesins in yeast cells, our results would more clearly and directly suggest the phenomena causing in CFEOM3 patients. "
2) The authors report that co-expression of the mutant tubulins is sufficient to cause a large disruption of both axonal transport and binding of kinesins to microtubules in extracts. In the discussion they assume that the effect they observe is the same as found in axonal cells in vivo. However as the authors point out the tub3 mutant isoform may only form some 10% of the total tubulin in vivo when expressed as one of the endogenous genes. In this paper the authors ectopically express the tubulin mutants in cultured cells but do not directly measure the level of the mutant tubulin protein expressed. They should therefore make clear in the discussion that their results only apply to the unknown level of mutant tubulin expressed in the cells in their tests.
We clearly described it in the discussion as followings: "Because our assay used CMV and CAG promoters and unknown copy numbers of transfected vectors, we could not quantify the amount of tubulin incorporated into microtubules in our system. However, we think our results give some indication to this question. Microtubules are composed of a-and b-tubulin dimers. The size of each tubulin dimer is 8 nm (Nogales et al, 1999) . Our analysis showed that TUBB3(E410K) and TUBB3(D417H) were incorporated to microtubules in cells and could inhibit axonal transport (Figures S1 and 8A) . The inhibition of motor domain accumulation, axonal transport and axon development were not observed when the incorporation of mutant tubulin was perturbed by introducing the additional S172P mutation (Figures 8 and 9) . Thus, these tubulin mutants need to be co-assembled with normal microtubules to induce neuronal phenotypes. If the 10% mutant TUBB3 is properly incorporated and evenly distributed in neuronal microtubules in CFEOM3 patients, the distance between TUBB3 mutants is about 80 nm, meaning that KIFdependent axonal transport is affected every 80 nm ( Figure 9D ). This distance is short enough to cause an effect because the length of axonal transport is in the order of millimeters to meters (Hirokawa et al, 2010) . To more quantitatively analyze this, it needs to quantify how much amount of mutant tubulin is incorporated to microtubules. It would be helpful to analyze neurons developed from inducible pluripotent stem cells of patients (Abeliovich & Doege, 2009 ). Fig 8d (p13L6) speculates on a potential mechanism to explain the action of low mutant tubulin concentrations incorporated in microtubules. This should be moved to the discussion. We moved this to discussion.
That blockage of axonal transport and kinesin binding could be caused by a 10% expression level and is the actual cause of the defects observed in neurological disease is still speculative and remains to be definitively shown. The model illustrated in

P15 Authors assume that the 10% level is sufficient to explain effect. This needs revising. Also unclear that in vivo the mutant tubulins are still only forming 10% of total tubulin.
We totally agree with the reviewer. It's unclear whether or not the mutant tubulin is properly expressed and incorporated in CFEOM3 patients. Thus, we rewrite the discussion as following: " If the 10% mutant TUBB3 is properly incorporated and evenly distributed in neuronal microtubules in CFEOM3 patients, the distance between TUBB3 mutants is about 80 nm, meaning that KIF-dependent axonal transport is affected every 80 nm ( Figure 9D ). "
3) Many of the images (fig1 and elsewhere) appear saturated making it difficult to visually verify the claims on localisation and expression levels. Images should be adjusted to avoid saturation.
We improved data presentation. However, some figures like Figure S1B , we intentionally present saturated images to clearly show our message. These are clarified in figure legends. Moreover, please see previous papers that use the same approach. To show cell bodies, axons and growth cones simultaneously, it was inevitable to saturate signals in cell bodies especially when signals are not concentrated to axons or growth cones. For quantification, we used 16-bit images and it was possible to measure without saturation.
4) P5 L16 "strongly affected" The difference seems small. These statements need to be backed by quantitation. Images of the other mutants should be shown in supplementary data.
We showed the data of TUBB3(E410K) in the revised manuscript (new Figure 1A) because it is important. Furthermore, we quantified the axon-to-dendrite signal ratio (Supplementary Figure  1C) 
5) P4 L1, p13 The authors state their aim as providing insight into basic molecular mechanisms of neuronal morphogenesis. Whilst this present approach certainly has promise of this in the future there is nothing in the current work to illustrate this. This speculation should be limited to the discussion.
We moved it to the discussion.
6) P4 L18 and figS1 legend states that L228P is cytoplasmic. However fig S1 shows some structures in the cytoplasm, which are not visible in the other "cytoplasmic" mutants. If these are not microtubules the authors should explain what they are.
As Reviewer#2 writes, L228P mutant is partially incorporated to microtubules. Thus, we explained our results more precisely in the revised manuscript as following: " The TUBB2(S172P) and TUBB2(T312M) mutants were cytoplasmic, and the TUBB2(L228P) mutant was partially incorporated to microtubules. "
7) P6 L15 fig1c (also fig2 etc). The most significant effect in the mutants seems to be pausing of the vesicles. The authors should comment on this. Also the comment (L19) that only a few vesicles were observed might suggest that loss of vesicle attachment is the main cause of loss of transport rather than slower movement or any of the other parameters mentioned.
We described it in the discussion in the revised manuscript.
"In the live cell imaging, the most obvious effect of these mutants is that they reduce the number of moving vesicles (Figure 1 and 2) . It suggests that loss of vesicle attachment is the main cause of loss of transport. This is supported by the biochemical data showing that the binding of KIFs is changed by these TUBB3 mutants (Figure 3) We changed the expression more precisely. "While most endogenous KIF5 was bound to microtubules in control cells in the presence of AMP-PNP, a significant amount of KIF5 was detected in the cytoplasmic fraction in TUBB3(E410K)-and TUBB3(D417H)-expressing cell lysates ( Figure 3A) ."
9) P10 L10 onwards. The authors argue that since Kif21 mutants associated with disease cause similar effects to the tubulin mutants in their assay the tubulin mutants must reflect a "diseaseassociated state" and therefore that E410 and D417 can change the properties of Kifs in neurons.
This seems a rather large inference to make.
We described the results more precisely as following: " A mutation in the KIF21A motor domain (C28W) has been reported to cause a neuronal disease, congenital fibrosis of extraocular muscle type 1 (CFEOM1) (Lu et al, 2008; Yamada et al, 2003) . In addition, we have shown that a rigor mutation (T90N) perturbs motor activity (Nakata & Hirokawa, 1995) . We therefore expressed these motor domain mutants in hippocampal neurons, and indeed, these two mutations changed KIF21A accumulation in axonal tips ( Figure 5B ). "
Other minor points:
P4 L13 Needs references for the mutants. We added references.
P6 L5 states 10 obervations, figure legend states n=6
10 is correct.
P11 L5. The structural data does not "predict" the effect of the tubulin mutants on accumulation of Kif2
We changed the expression.
P11 L19 Tub3 was the only gene analysed up to this point.
We deleted the sentence because it is not needed.
P13 L22 authors state E410K and D417H are specific. Next sentences says other mutants are "more specific" unclear what they mean.
Fig1b graph. The graph needs to clearly show how many time points are included. Would a bar
chart not be more appropriate as the time differences are not constant the lines joining the data points are misleading. Yes. As the bar chart is more appropriate, we changed.
Fig4a "Graphs indicated the statistical analysis" Not indicated what the error bars represent or what comparison the t test refers to.
Means ± SD is correct.
Fig 6c Kymogrpah axes are not annotated.
We added the annotation. We asked a professional English rewriting service to correct our revised manuscript.
We appreciate Reviewer#2 again for his careful reading and many suggestions.
Referee #3 Niwa and Hirokawa report a series of experiments providing molecular explanation for inhibition of axonal transport of vesicles and mitochondria in neuronal diseases caused by certain mutations in beta-tubulin. The authors demonstrate that two mutations occurring in H12 helix of beta-tubulin, affect the binding of kinesin motors by changing the charge of this alpha-helix and thereby reducing the affinity of kinesins for beta-tubulin. The manuscript is clearly written and the work could be interesting to the broad spectrum of EMBO readers. However, there are several major (especially the effect on dynein, mitochondria / VAMP2 quantifications and the effect on neuronal morphology)
and some minor issues that should be addressed first.
We deeply appreciate Reviewer#3 for supporting our paper to be published in the EMBO Journal and for providing useful and constructive suggestions. We revised our manuscript as described bellow:
It is stated that "Microtubules were not significantly affected by expression of these tubulin mutants as described before (data not shown)." The authors should show that these mutations in tubulin do not affect to posttranslational modifications like tyrosination or acetylation and perform live imaging experiments of microtubule dynamics.
As Reviewer#3 points out, the explanation is not precise and sufficient. We would like to write "the polymerization of endogenous microtubules are not inhibited". We showed it in the Supplementary Figure S1 . It has previously shown that some mutations affect the level of tyrosination and acetylation of tubulin and microtubule dynamics. However, it remained elusive whether or not these mutations change the axonal transport. The purpose of this study is to test this point. Figure 1A with GFP-VAMP2 on Figure S1B , it looks very much diffuse in the nucleus, soma, dendrites and axon on the later one. Why do this individual experiment look so different?
The authors use GFP-VAMP2 as a marker for vesicular axonal transport. It is written "Indeed, GFP-VAMP2 specifically accumulated in axons when co-transfected with WT-TUBB3 to hippocampal neurons at 10 div (Fig. 1A, left panel and supplementary Movie S1)". Subcellular localization of GFP-VAMP2 is consistent among the main figures. But if one compares GFP-VAMP2 on
The purpose of Figure S1B is to show the co-transfection in a broad field, while the purpose of Figure 1A is to show the localization of GFP-VAMP2 in cells. Thus, we took the photo using a low magnification and NA lens (x10, NA0.3) and showed a low resolution image with saturated signals in Figure S1B , while we presented a high resolution image of neurons using a high magnification and good NA lens (x100, NA1.46) in Figure 1A . This is clearly written in the Figure legend of the revised manuscript as following: "To show the co-expression in the broad field, saturated signals were intentionally shown in this figure. "( Figure S1B ) "Plan ApoChromat lens (x100, NA1.45) was used in high-resolution images, while Objective Plan We measured the ratio between axon and dendrites and presented as a graph (New Figure S1C) . We deeply thank Reviewer#3 for this constructive suggestion.
The number of mitochondria is moving in 5 min. What does that mean? This is not explained well in methods. How long was the axon region that was analyzed... ? How many mitochondria and cells taken into this analysis.
We are very sorry for this mistake. We counted the number of anterogradely-moving mitochondria passing a point in axons. Thus, the value is length independent. We add number of axons in the figure legends. " The number of anterogradely-moving mitochondria passing at a point in axons was counted for 5 min and plotted. Data are presented as means ± SD. *; p < 0.01, t-test, compared with WT cells. Ten axons from ten neurons that were obtained from three independent transfections were counted. " Figure 2A : The clearest difference was the reduction of motility as shown in Fig 2A . This is also consistent with the reduction of mitochondrial density (New Figure 2B) . As the number of moving mitochondria (and also vesicles) was significantly reduced as shown in kymographs, it was difficult to statistically analyze those motility parameters suggested by Reviewer#2. Furthermore, as far as we observed, microtubule-dependent intracellular transport is broadly affected by TUBB3(E410K) and TUBB3(D417H) mutations. Thus, it is difficult to show negative controls that are not affected by these tubulin mutations. We described them in the revised manuscript as following: "Although we tried to calculate other parameters such as run length, the number of changes of direction and the average speed, only a very few moving vesicles were observed in TUBB3(E410K)-and TUBB3(D417H)-expressing neurons; thus we could not observe a sufficient number of moving vesicles." (the Results section)
"As is the case in vesicle motility (Figure 1) , the most obvious effect was reduction of number of moving mitochondria; it was difficult to compare various motility parameters such as run length and changes of moving direction." (the Result section) "In the live cell imaging, the most obvious effect of these mutants is that they reduce the number of moving vesicles and mitochondria (Figure 1 and 2) . It suggests that loss of vesicle attachment is the main cause of loss of transport. This is supported by the biochemical data showing that the binding of KIFs is changed by these TUBB3 mutants (Figure 3) ." (the Discussion section) Using an anti-dynein antibody (Hirokawa et al, 1990) , we performed the same experiment. We found that E410K and D417H mutants do not affect the binding of dynein to microtubules (new Figure 3 ). This would be because the binding site of dynein is different from KIFs. Thus, it is discussed in the discussion as following: "Dynein was not affected in biochemical experiments, probably because the binding mechanism is different from KIFs. Nevertheless, retrograde transport was also reduced by these mutant tubulins. It would be the secondary effect of reduction of anterograde transport." (in the Discussion) According to the reviewer's suggestion, we performed in utero electroporation to show the cellular morphology in vivo. Results suggested that axonal elongation is severely affected in these neurons (new Figure 9) . As this reviewer kindly suggested, this phenotype is very similar to kinesinknockout mice. As an example, we newly showed in the revised manuscript that inhibition of KIF1Bb causes the same phenotype (new Figure 9) . Furthermore, these phenotypes are very similar to the symptoms of severe CFEOM3 patients whose brain axons are severely disrupted as discussed in the discussion. Thank you very much for this very constructive suggestion.
Minor criticisms:
1. The authors found that two TUBB3 mutants, TUBB3 (E410K) and TUBB3 (D417H), strongly affected the axon specific localization of central panel and graph) . But in the figure 1A they only show one of these mutation. Both mutants should be shown
We showed the results of both TUBB3(E410K) and TUBB3(D417H) mutants in the revised manuscript (New Figure 1A) .
Why most of E410K images have different signal-to-noise ratio compare to controls? Please make the necessary changes.
We revised the figure. As VAMP2 is not concentrated to axons, it is difficult to show unsaturated cell bodies in E410K-coransfected neurons. Fig 1B) This is a good suggestion that is also pointed out by Reviewer#2. As we would like to show the difference between WT-and tubulin mutant-expressing cells, we showed the fluorescent intensity after 5 min. We don't think there are significant meanings in the time course of recovery until they reach plateau because it will reflect not only the motility of vesicles but also the diffusion of plasmamembrane bound proteins. As the purpose of graph is to show what extent fluorescent signals recovered, but not to show the time course of the recovery, we changed the graph to the bar graph.
In the FRAP experiments (
Figure 4 -it would be better to convert all images on this figure to grey scale.
We converted the color to gray scale (New Figure 4) .
Additionally is it not clear how "tips" and "shafts" of axons are defined. Is the total length of axon (excluding the growth cone) measured as mean grey value and considered as "shaft" or only a fragment?
"Tips" and "shafts" mean growth cones and entire axons respectively. We defined them in the materials methods. Figure 5A does not exist, should this be S2A? Figure 5A is correct.
Supplementary
"As control experiments
showing that the accumulation in hippocampal neurons reflect the activity of KIFs and can detect disease-associated deficiency of motor proteins, we expressed a rigor mutant of KIF21A (Nakata & Hirokawa, 1995) , and a KIF21A mutant causing a neuronal disease, congenital fibrosis of extraocular muscle type 1 (CFEOM1) (Lu et al, 2008; Yamada et al, 2003) . Introducing of these two mutants into GFP-hKIF21A420 changed the tipaccumulation ( Fig  5B) We described these results more precisely as following: "A mutation in KIF21A motor domain (C28W) is reported to cause a neuronal disease, congenital fibrosis of extraocular muscle type 1 (CFEOM1) (Lu et al, 2008; Yamada et al, 2003) . We have shown that a rigor mutation (T90N) perturbs motor activity (Nakata & Hirokawa, 1995) . To test whether or not the tip accumulation in hippocampal neurons is changed by these motor domain mutations that changes the localization, we expressed them in hippocampal neurons. Accordingly, these two mutations changed the tip accumulation (Fig 5B) . "
How do the authors know that they have at least 10% mutant tubulin incorporated. The data should be shown.
We totally agree with the reviewer that, in our experiment, it is impossible how much tubulin is incorporated to microtubules. Nevertheless, we would like to discuss the condition of patient brains. It is known that TUBB3 is about 20% of total tubulin (Joshi & Cleveland, 1989 ) and the disease is caused by dominant manner (Tischfield et al, 2010) . Of course, it needs to be determined whether or not mutant tubulins are properly expressed and incorporated to microtubules in patients' brains in the future study. We included, in the discussion, the limitation of our experiments and our insight as described below: " Because our assay used CMV and CAG promoters and unknown copy numbers of transfected vectors, we could not quantify the amount of tubulin incorporated into microtubules in our system. However, we think our results give some indication to this question. "
" If the 10% mutant TUBB3 is properly incorporated and evenly distributed in neuronal microtubules in CFEOM3 patients, the distance between TUBB3 mutants is about 80 nm, meaning that KIF-dependent axonal transport is affected every 80 nm ( Figure 9D )." As Reviewer#2 points out, previous supplementary Figure 2 is problematic. Thus, we newly performed tau staining in non-transfected cells. Furthermore, we improved the figure to clarify the axon in KIF1B470-tansfected cells (New Figure S2) . Figure 5A is not described in the text.
9.
We are very sorry for this mistake. We described it in the revised manuscript.
Some symbol letters appears like &#x25A1; in Methods
These errors were caused when the manuscript was converted to PDF on the EMBO Journal's server. We corrected these disorganizations as far as possible. Furthermore, we asked professional English editor to proofread our manuscript.
Finally we deeply thank all reviewers again for his or her warm and constructive suggestions. Through the discussion with them, we believe we could significantly improve our manuscript. Thank you very much!
